What’s the comparison between the slabs?

The primary slab patients need to determine treatments as soon as they are diagnosed, and the most common treatments are hydroxylazine, interfluent and Anagraine, but how are the three treatments chosen and compared? The CBSA micro-link public number: xxbzd9991, HYGY: HYGYLZO is used for the early treatment of genuine erythrocytes, and for patients with more serious conditions, such as the normal slab count, usually at 100 ~ 300 x 10 > 9/L, when the slab count of the patient with SB is higher than 1,000 x 10 ^ 9/L, recommends treatment with HBCD, which can be rapidly reduced to control. Interference: Correspondingly, it is applied to young patient groups and in less serious cases. Interferogenic treatment can reduce the genetic load to a certain extent for patients with genetically mutagenic slabs, so that for patients with oxytocin impatience they can also choose to control the condition. 3. Anagre: Anagre is suitable for patients who are resistant to GHB, especially young people, and wants to avoid the potential risk of its long-term use. However, the prices of Anagray are less affordable than those of hydroxygen and interferon, and therefore need to be considered together. It should be noted that the long-term increase in the incidence of pre-emergence slabs requires more long-term medication, and it is recommended that patients with screen slabs be better equipped to manage their complications in order to improve their quality of life and improve their prognosis, with the option of joint treatment for mitigation if necessary, subject to medical advice. In the light of the above, there are limitations to the choice of any treatment for people with pre-existing hemoplasis, so it is for them to be the relatively best. Following treatment, in addition to active cooperation with doctors, regular visits are made to monitor changes in conditions.